COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes

Lattenist, Raphaël; Yıldız, Halil; Greef, Julien De; Bailly, Sarah; Yombi, Jean Cyr

doi:10.1007/s12288-020-01318-4

Cited by 19 publications

(45 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 ] Peer reviewed 13 8 23 Jan to 14 Feb 2020 Union Hospital and Wuhan Central Hospital, China Haematological malignancies only 50 Lattenist et al. [ 56 ] Peer reviewed 13 6 13 Mar to 15 May 2020 Universite´ catholique de Louvain, Brussels, Belgium Haematological malignancies only 51 Yu et al. [ 57 ] Peer reviewed 12 3 30 Dec 2019 to 17 Feb 2020 Wuhan, China Any 52 Wu et al.…”

Section: Resultsmentioning

confidence: 99%

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Saini

Tagliamento

Lambertini

et al. 2020

European Journal of Cancer

298

275

View full text Add to dashboard Cite

Background Patients with coronavirus disease 2019 (COVID-19) who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19. Methods A systematic literature search involving peer-reviewed publications, preprints and conference proceedings up to July 16, 2020, was performed. The primary end-point was the case fatality rate (CFR), defined as the rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI). Results Fifty-two studies, involving a total of 18,650 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 4243 deaths were recorded in this population. The probability of death was 25.6% (95% CI: 22.0%–29.5%; I 2 = 48.9%) in this patient population. Conclusions Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer and to optimally manage those who do contract the infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Saini

Tagliamento

Lambertini

et al. 2020

European Journal of Cancer

298

275

View full text Add to dashboard Cite

show abstract

“… 100 Lattenist and others found patients with hematologic malignancies to be vulnerable to SARS-CoV-2, with age and low hemoglobin levels to be risk factors for poor outcome. 101 In one study, elderly patients (age > 65 years) with hematologic cancers did not have an increased risk of death following COVID-19. 102 …”

Section: Covid-19 Infections In Patients With Hematological Disordersmentioning

confidence: 95%

Hematological Abnormalities in COVID-19: A Narrative Review

Rahman

Niloofa

Jayarajah

et al. 2021

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

COVID-19 is caused by SARS-CoV-2. Although pulmonary manifestations have been identified as the major symptoms, several hematological abnormalities have also been identified. This review summarizes the reported hematological abnormalities (changes in platelet, white blood cell, and hemoglobin, and coagulation/fibrinolytic alterations), explores their patho-mechanisms, and discusses its management. Common hematological abnormalities in COVID-19 are lymphopenia, thrombocytopenia, and elevated D-dimer levels. These alterations are significantly more common/prominent in patients with severe COVID-19 disease, and thus may serve as a possible biomarker for those needing hospitalization and intensive care unit care. Close attention needs to be paid to coagulation abnormalities, and steps should be taken to prevent these occurring or to mitigate their harmful effects. The effect of COVID-19 in patients with hematological abnormalities and recognized hematological drug toxicities of therapies for COVID-19 are also outlined.

show abstract

“…These complications were most often the result of bacterial coinfections which were attributed to impaired immune system function from their disease process as well as disease treatment. Risk factors in this patient population appear to be linked to older age as well as immune and disease status [ 2 , 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have investigated outcomes in COVID-19 patients with active hematologic malignancy, with evidence of worse outcomes in this cohort [ 1 ]. Parameters such as older age, immune and disease status, and performance status have been shown to be related to mortality in patients with active disease as well as those in remission [ 2 , 3 ]. The potential role of sickle cell disease (SCD), an immunocompromised state, in increased morbidity and mortality has also been described in various case series and studies [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 in Patients With Hematologic-Oncologic Risk Factors: Complications in Three Patients

Tafti

Kluckman

Dearborn

et al. 2020

Cureus

View full text Add to dashboard Cite

COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes

Cited by 19 publications

References 5 publications

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Hematological Abnormalities in COVID-19: A Narrative Review

COVID-19 in Patients With Hematologic-Oncologic Risk Factors: Complications in Three Patients

Contact Info

Product

Resources

About